Precision BioSciences doses first patient in CAR T cell therapy trial
Category: #health  By Nikita Chaurasia  Date: 2019-04-19
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Precision BioSciences doses first patient in CAR T cell therapy trial
  • Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm
     
  • The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL

The US-based genome editing firm Precision BioSciences has reportedly announced that it has successfully administered the dosage of its very first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate, PBCAR0191, in the Phase 1/2a clinical trial. As per trusted sources, PBCAR0191 is developed from T cells derived from donors which are then altered by utilizing the ARCUS genome editing technology of Precision.

Reportedly, the alterations are designed to create CAR T cells which specifically distinguish CD19 – a significant target in several B-cell cancers – to prevent graft-versus-host ailment. According to a press release by Precision BioSciences, the CAR T cell is being assessed in adult patients with relapsed or refractory non-Hodgkin lymphoma or as an off-the-shelf cell therapy.

The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL.  This open label, multi-center study of PBCAR0191 is anticipated to register a minimum of 80 patients and numerous dose level of PBCAR0191 would be investigated.

According to a press release by Precision BioSciences, the clinical sites include MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Moffit Cancer Center, and City of Hope. Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm.

For the record, the basic goal of the trial is to assess the safety of PBCAR0191 and decide upon the maximum tolerated dose. The secondary goal is to assess the anti-tumor activity of PBCAR0191.

As per reliable sources, the outcomes of the trail would be collected for up to one year.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

CDC warns of severely high COVID-19 transmission rate in U.S. counties

CDC warns of severely high COVID-19 transmission rate in U.S. counties

By Nikita Chaurasia

The United States Centers for Disease Control and Prevention (CDC) has warned that 66.6% of the total U.S. counties still have a high risk of acquiring or transmitting COVID-19. The regulatory body has also updated its guidelines, recommending even v...

Beijing’s quota clampdown could inhibit China’s crude oil import growth

Beijing’s quota clampdown could inhibit China’s crude oil import growth

By Nikita Chaurasia

According to a study conducted by Independent Commodity Intelligence Services (ICIS), China's growth in oil imports is expected to plummet to the lowest level in two decades during 2021, even with an estimated surge in refining rates during the l...

3D-model platform Sketchfab becomes Epic Games’ next big acquisition

3D-model platform Sketchfab becomes Epic Games’ next big acquisition

By Nikita Chaurasia

After RAD Game Tools and Quixel Megascans, American video game and software development company Epic Games Inc. has now acquired Sketchfab, the platform that boasts of over 4 million 3D models where artists can publish, modify, and sell their creatio...